PD-1 vs PD-L1 Therapy in Advanced Merkel Cell Carcinoma

This international retrospective study compares the effectiveness of anti–PD-1 therapies (pembrolizumab, nivolumab, retifanlimab) versus anti–PD-L1 therapy (avelumab) in patients with advanced Merkel cell carcinoma (MCC). 

More information coming soon.